SCHEMBL396456

SCHEMBL396456

Cc1cccc(C(=O)Nc2cccc(Oc3ccc4c(c3)NC(=O)C4=Cc3cc(C(=O)NCCCN(C)C)c[nH]3)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 6/20 0.52
PDPK1 O15530 3/20 0.51
PDK1 Q15118 1/20 0.51
NTRK1 P04629 4/20 0.45
NTRK2 Q16620 2/20 0.45
TLK2 Q86UE8 2/20 0.42
KDR P35968 3/20 0.41
KIT P10721 1/20 0.41
FLT4 P35916 1/20 0.41
FLT3 P36888 1/20 0.41
NTRK3 Q16288 2/20 0.41
MCHR1 Q99705 1/20 0.41
PAK4 O96013 1/20 0.41
FLT1 P17948 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091933 1.00 AKT2 (0.52) AKT2PDPK1PDK1NTRK1NTRK2
SCHEMBL396426 0.91 NTRK1 (0.53) AKT2PDPK1PDK1NTRK1NTRK2
SCHEMBL10091931 0.91 NTRK1 (0.53) AKT2PDPK1PDK1NTRK1NTRK2
SCHEMBL10091936 0.90 AKT2 (0.46) AKT2PDPK1PDK1NTRK1NTRK2
SCHEMBL394066 0.90 AKT2 (0.46) AKT2PDPK1PDK1NTRK1NTRK2
SCHEMBL10091934 0.88 AKT2 (0.53) AKT2PDPK1NTRK1NTRK2KDR
SCHEMBL398656 0.88 AKT2 (0.53) AKT2PDPK1NTRK1NTRK2KDR
SCHEMBL398702 0.87 KDR (0.53) AKT2NTRK1NTRK2TLK2KDR
SCHEMBL398703 0.87 KDR (0.53) AKT2NTRK1NTRK2TLK2KDR
SCHEMBL10091935 0.85 AKT2 (0.60) AKT2PDPK1NTRK1NTRK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed